Form 4: Amarin Executive Granted Stock Options

Jonathan Provoost, EVP and Chief Legal Officer at Amarin, was granted stock options for 663,878 ordinary shares on January 10, 2025.

Summary

• Jonathan Provoost, the EVP and Chief Legal Officer of Amarin, received stock options for 663,878 ordinary shares.
• The grant occurred on January 10, 2025.
• The exercise price is $0.62 per share.
• The options vest over 18 months, with 50% vesting on the first anniversary of the grant date and the remaining 50% vesting six months later.
• The options expire on January 10, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in publicly traded companies, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation across the pharmaceutical industry.
• The vesting schedule of 18 months is fairly typical, designed to incentivize long-term performance and retention.
• The exercise price is set at the higher of the nominal par value or the fair market value at the time of grant, which is a common practice to ensure the options have value.

Stakeholder Impact

• Shareholders may view this positively as it aligns executive interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, equity, vesting, Amarin, AMRN, Jonathan Provoost